BayerW.L.BodensteinerD.C.TilzerL.L.AdamsM.E.: Use of platelets and other transfusion products in patients with malignancy.Semin Thromb Haemost, 18: 380–391, 1992.
2.
National Institutes of Health Consensus Conference.Platelet transfusion therapy.Transfus Med Rev, 1: 195–200, 1987.
3.
SlichterS.J.: Principles of platelet transfusion therapy.In: Hematology. Basic principles and practice, HoffmanR, BenzEJJr., FurieS.J. B Shattil, CohenHJ (Eds), pp 1610–1622, Churchill Livingstone, New York, 1991.
4.
GaydosL.A.FreireichE.J.MantelN.: The quantitative relation between platelet counts and hemorrhage in patients with acute leukemia, N Engl J Med, 266: 905–909, 1962.
5.
HeymanM.R.SchifferC.A.: Platelet transfusion therapy for the cancer patient.Semin Oncol, 17: 198–209, 1990.
6.
SlichterS.J.HarkerL.A.: Thrombocytopenia: mechanisms and management of defects in platelet production.Clin Haematol, 7: 523–528, 1978.
7.
SacherR.A.LubanN.L.C.StraussR.G.: Current practice and guidelines for the transfusion of cellular blood components in the newborn.Transfus Med Rev, 3: 39–54, 1989.
8.
British Committee for Standards in Haematology.Guidelines for platelet transfusion.Transfus Med, 2: 311–318, 1992.
9.
The Royal College of Physicians of Edinburgh.Consensus conference. Leucocyte depletion of blood and blood components. Edinburgh, 1993.
10.
NorfolkD.R.AncliffeP.J.ContrerasM.HuntB.J.MachinS.J.MurphyW.G.WilliamsonL.M.Consensus conference on platelet transfusion, Royal College of Physicians of Edinburgh, 27–28 November 1997. Synopsis of background papers.Br J Haematol, 101: 609–617, 1998.
11.
RebullaP.: Rischio emorragico e trasfusione di piastrine.In: II rischio emorragico nelle piastrinopenie, BarbulT, FinazziG (Eds), pp 177–206, Piccin, Padova, 1999.
12.
HeatonW.A.L.RebullaP.PappaletteraM.DzikW.H.for the BEST Working Party of the International Society of Blood Transfusion: A comparative analysis of different methods for routine blood component preparation.Transfus Med Rev, 2: 116–129, 1997.
13.
BurgstalerE.A.: Current instrumentation for apheresis.In: Apheresis: principles and practice, McLeodBC, PriceTH, DrewMJ (Eds), pp 85–112, AABB Press, Bethesda, 1997.
14.
ZingsemJ.ZimmermannR.WeisbachV.GlaserA.van WaegG.EcksteinR.: Comparison of COBE white cell-reduction and standard plateletpheresis protocols in the same donors.Transfusion, 37: 1045–1049, 1997.
15.
HauserS.P.SchallerM.NydeggerU.E.: Quality assurance in thrombapheresis.Transfus Sei, 20: 73–77, 1999.
16.
Lopez-PlazaI.WeissfeldJ.TriulziD.J.: The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets.Transfusion, 39: 925–932, 1999.
17.
CarmenR.: The selection of plastic materials for blood bags.Transfus Med Rev, 7: 1–10, 1993.
18.
GmürJ.BurgerJ.SchanzU.FehrJ.SchaffnerA.: Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia.Lancet, 338: 1223–1226, 1991.
19.
SeymourJ.: Prophylactic platelet transfusion in acute leukaemia.Lancet, 339: 120, 1992.
20.
GmürJ.SchaffnerA.: Prophylactic platelet transfusion in acute leukaemia.Lancet, 339: 120–121, 1992.
21.
Gil-FernandezJ.J.AlegreA.Fernandez-VillaltaM.J.PinillaI.Gomez GarciaV.MartinezC.TomasJ.F.ArranzR.FigueraA.CamaraR.Fernandez-RanadaJ.M.: Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution.Bone Marrow Transplant, 18: 931–935, 1996.
22.
LawrenceJ.B.YomtovianR.HammonsT.MasarikS.LazarusH.M.: Lowering the prophylactic platelet transfusion (Pro-PltTx) trigger: a prospective analysis.Transfusion, 34(Sup-pi), 53S, 1994.
23.
HeckmanK.D.WeinerG.J.DavisC.S.StraussR.G.JonesM.P.BurnsC.P.: Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/μL versus 20,000/μL.J Clin Oncol, 15: 1143–1149, 1997.
24.
RebullaP.FinazziG.MarangoniF.AvvisatiG.GugliottaL.TognoniG.BarbuiT.MandelliF.SirchiaG.for the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto: The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia.N Engl J Med, 337: 1870–1875, 1997.
25.
WandtH.FrankM.EhningerG.SchneiderC.BrackN.DaoudA.Fackler-ShwalbeI.FischerJ.GäckleR.GeerT.HarmsP.LöfflerB.OhlS.OtrembaB.RaabM.Schönrock-NabulsiP.StrobelG.WinterR.LinkH.: Safety and cost effectiveness of a 10 × 109/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia.Blood, 91: 3601–3606, 1998.
26.
LeverettD.NultyK.StavesJ.DoddsD.MachinS.J.GoldstoneA.H.DevereuxS.: Clinical and economic effects of lowering the threshold for prophylactic platelet transfusion.Br J Haematol, 105(suppl 1), 30, 1999.
27.
RoyA.J.JaffeN.DjerassiI.: Prophylactic platelet transfusions in children with acute leukemia: a dose response study.Transfusion, 13: 283–290, 1973.
28.
DutcherJ.P.SchifferC.A.AisnerJ.WiernikP.H.: Alloimmunization following platelet transfusion: the absence of a dose response relationship.Blood, 57: 395–398, 1981.
29.
StraussR.G.: Clinical perspectives of platelet transfusions: defining the optimal dose.J Clin Apheresis, 10: 124–127, 1995.
30.
HermanJ.H.KlumppT.R.ChristmanR.A.RussoR.R.GoldbergS.L.ManganK.F.: The effect of platelet dose on the outcome of prophylactic platelet transfusion (abstract).Transfusion, 35(suppl): 46S, 1995.
31.
NorolF.BierlingP.Roudot-ThoravalF.Ferrer Le CoeurF.RieuxC.LavauxA.KuentzM.DuedariN.: Platelet transfusion: a dose-response study.Blood, 92: 1448–1453, 1998.
32.
HershJ.K.HornE.G.BrecherM.E.: Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronically platelet transfusion-dependent patient.Transfusion, 38: 637–644, 1998.
33.
KlumppT.R.HermanJ.H.GaughanJ.P.RussoR.R.ChristmanR.A.GoldbergS.L.AckermanS.J.BleeckerG.C.ManganK.F.: Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial.Transfusion, 39: 674–681, 1999.